Year: 2023
Type: dissertation
Study design: Observational Study
Abstract: Sickle cell anemia (SCA) is the most common hemoglobinopathy worldwide. Developing countries like the Democratic Republic of Congo (DRC) suffer a heavy burden and the disease-related mortality remains high, up to 50% to 90% before five years of age. Factors that contribute to high mortality include delayed diagnosis due to the scarcity of appropriate laboratory infrastructure, poor access to adequate medical care due to limited financial resources of patients, inadequate supply of state-of the art medical, prevailing mystical beliefs and use of traditional herbal medicine. Despite the fact that a single mutation in the β globin gene causes SCA, a marked interindividual variability in clinical manifestations and severity as well as the response to hydroxyurea (HU) is observed among SCA patients. Genetic factors are among factors that could explain this variability. We conducted this study to improve the care to SCA patients though accurate, rapid and efficient diagnostic and a better understanding of the influence of genomic polymorphisms on clinical and biological profile and on the response to HU treatment in Congolese SCA patients. The overall cohort consisted of 338 patients of whom 102 were neonates, 236 children and adults. Neonates were recruited at 2 maternities of Kinshasa i.e. Maternity of Binza and Maternity of Kingasani. Recruitment for children and adults were performed respectively at the Saint Luc Hospital in Kisantu (Kongo central Province) and the "Centre de Médecine Mixte et d'Anémie SS (CMMASS)" , St Crispin Hospital , and University Hospitals of the University of Kinshasa at Kinshasa (the capital city) . All sites are located in the DRCongo. In the first part, we aimed to implement a DNA-based SCA test that would be suited for a limited resource setting and overcome limitations of hemoglobin (Hb)-based tests commonly used in the current standard of care. The SCA Hb-based tests are not reliable particularly in neonatal and post-transfusion periods. Three types of biological samples were collected: venous blood, umbilical cord blood (UCB) and buccal swab. A drop of blood (approximately 50 μl of blood) (venous and UCB) was deposited on a circle of an FTA Elute card (Whatman WB120206).Buccal swabs collected using a homemade sterile swab, was also rubbed on a circle of FTA elute card for 10 seconds in order to transfer the sample. After DNA extraction by the manual salting out method (SO), SCA molecular testing (RFLP) was performed to identify the sickled mutated allele (SO-RFLP method). We adapted the SO-RFLP protocol by replacing the extracted DNA sample by a 1.2 mm punch of FTA Elute cards, thus avoiding an expensive DNA extraction step. There was a perfect agreement between both protocols i.e. SO-RFLP and FTA-RFLP. By skipping the DNA extraction step, the FTA-RFLP reduces the cost by half (from 11.5 € to 6.5 €) and turn-around time significantly. FTA Elute cards with blood spots were conserved in a clean closet at room temperature (RT) and retested after 2 years. We obtained the exact same results. The value and utility of DNA-based test on DBS in post-transfusion period is an ongoing study where FTA-RFLP is performed before and 1 hour after a blood transfusion. Our preliminary results (on 6 patients) show that the yield of FTA-RFLP remains unchanged after packed cells transfusion contrary to the two Hb-based tests. Thus, the FTA-RFLP can be recommended as (1) a first-tier diagnostic test for newborns from high risk couples (both partners are heterozygotes) and (2) as the second-tier test for newborns with inconclusive or positive results at the standard newborn screening without having to wait the 3 months period. The test can also be offered immediately after transfusion, avoiding the currently long waiting time required for a reliable Hb electrophoresis The easy transportation as well as the proven good conservation of samples suggests that FTA Elute card is a suited collection device in a resource limited setting. Moreover, storage at RT makes access to cold storage facilities unnecessary, which is a critical advantage in developing countries where electricity supply is unreliable In the second part, we focused on the evaluation of genetic factors involved in modulating the clinical and biological expression of SCA, as well as the pharmacogenetics of HU. We first assessed the distribution of βS-globin haplotypes and the correlation between haplotypes and baseline hematological and clinical profiles in our cohort of patients recruited at the Saint Luc Hospital in Kisantu and the "Centre de Médecine Mixte et d'Anémie SS (CMMASS)". Patients were classified according to the clinical phenotype score as previously described. Then we evaluated a set of single nucleotide polymorphisms (SNPs), for their potential association with HbF levels and the hematological parameters involved in the disease severity. Finally, we determined the contribution of α-thalassemia coinheritance, the βs haplotypes and candidate SNPs in HU response in the set of patients within our initial cohort , who were included in a HU clinical trial. Prior to be included in this part of the study, SCA homozygous status had to be confirmed by DNA testing as previously described. In addition, we excluded in confirmed SCA patients, those not in a steady state of the disease, those who received a transfusion within 4 months prior to blood sample collection, and those under Hydroxyurea treatment. For each participant, peripheral blood was collected in two EDTA-coated tubes of 4ml for hematologic tests and DNA extraction. Measured hematologic parameters were: hemoglobin (Hb), white blood cells (WBC), platelets (PLT), and reticulocytes (RETIC). The HbF level was quantified by capillary electrophoresis (Minicap, SEBIA, France). Genomic DNA was extracted from blood samples using the salting out method. We used a candidate SNP approach exploring only SNPs with previously reported associations in the literature and public databases. Candidate SNPs associated with the baseline HbF level were retrieved from literature, searching PubMed using "fetal hemoglobin polymorphisms". We also extended the search to relevant papers from the reference lists of articles retrieved through Pubmed search. We also searched in GWAS Catalog using " fetal hemoglobin" AND "sickle cell anemia". The candidate SNPs associated with Hydroxyurea-induced HbF level were also retrieved through the same process using "fetal hemoglobin" AND "Hydroxyurea". We also extend the research to the PharmGKB database using "fetal hemoglobin hydroxyurea". Our SNP set contained the 4 polymorphic positions defining the five βs- globin haplotypes . In addition, 63 SNPs were included in the study of other genomic modifiers exerting pharmacogenomic variants. All these single nucleotide polymorphisms (SNPs) were genotyped at once using Molecular Inversion Probes (MIP) method. The α-thalassemia status was determined using the multiplex ligation-dependent probe amplification( MLPA) method. The haplotype CAR was the predominant allele (95.92%), followed by BEN (1.67%), SEN (1.31%), and AI (0.37%). Atypical haplotypes accounted for 0.74 % of alleles. Six haplotypic genotypes were identified, including homozygous CAR (92.2%), homozygous BEN (0.37%), and double heterozygous CAR/BEN (2.59%), CAR/SEN (2.59%), CAR/AI (0.74%) and CAR/ATYP (1.48%). Less than 15% of patients within the CAR/CAR haplotype presented a severe clinical phenotype , representing 11% among children and 8% among adults. Concerning the HbF baseline levels, the most significant association with HbF level was found for rs1427407 at BCL11A loci, with the highest level of HbF (13.8%) in homozygous TT genotype. Other SNPs within BCL11A locus (rs766432, rs11886868, rs4671393,rs7606173) and HBS1L-MYB intergenic region (rs28384513) were also significantly associated with HbF levels. No simultaneous association with HbF and hematologic variables was observed for any of these SNPs. Only the OR51B5/6 loci with rs5006884 and rs5024042 were associated with platelet count. We conclude that βs haplotypes are not the major explanation for the clinical and biological variability in Congolese patients as patients still have variable hematologic and clinical profiles. This biological variability is explained by genomic loci that are identical across the sub-Saharan regions. The coinheritance with α-thalassemia as well as βs haplotypes did not influence the HU response in term of HU-induced HbF level. A set of six SNPs rs 28384513 (HBS1L-MYB), rs 1480642 and rs 487278 (PDE7B), rs 9483947 (MAP3K5), rs 765587 (TOX) and rs 9319428 (FLT1) were significantly associated with HU-induced HbF levels. These set of SNPs may serve as predictors of HU response in our setting.
Source: Lirias
Author: Ngole Zita, Mamy
Institution: KU Leuven
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7038038580
